Abstract
BackgroundThe objective of this study was to construct and validate a brief, clinically-relevant symptom index for advanced prostate cancer.MethodsQuestions were extracted from a commonly-used multi-dimensional cancer quality of life instrument with prostate-specific items, the Functional Assessment of Cancer Therapy-Prostate (FACT-P). Surveys of disease-related symptoms were presented to an international sample of 44 expert physicians. Each expert narrowed the list to no more than five of the most important symptoms or concerns to monitor when assessing the value of treatment for advanced prostate cancer. Symptoms/concerns endorsed at a frequency greater than chance probability (17%) were retained for the symptom index and called the FACT Advanced Prostate Symptom Index-8 (FAPSI-8): pain (three items), fatigue, weight loss, urinary difficulties (two items), and concern about the condition becoming worse. The FAPSI-8 was validated using data from a clinical trial of 288 men being treated for hormone refractory prostate cancer.ResultsThe FAPSI-8 showed good internal consistency (r = 0.67–0.80); association with existing FACT scales (e.g., FACT-P, Physical Well-being, Functional Well-being; r = 0.44–0.85, p < .0001), responsiveness to clinical change (Guyatt's Responsiveness statistic = 1.29), and ability to differentiate patients by performance status (p < .0001). A six-item alternate version of the FAPSI was also evaluated with comparable results.ConclusionsThis project produced a reliable and valid list of the eight most important clinician-rated targets of drug therapy for advanced prostate cancer. These questions perform comparably to the longer derivative questionnaire. Examination of patient agreement with this priority list and the extent to which changes in these 8 targets are related to meaningful clinical benefit to the patient are important next steps for future research.
Highlights
The objective of this study was to construct and validate a brief, clinically-relevant symptom index for advanced prostate cancer
In phase 2, we presented the Survey to an international sample of physician experts for selection of the highest priority symptoms to evaluate when treating men with advanced prostate cancer
Survey Of the symptoms/concerns presented to physician experts (Table 2), eight items were endorsed with a greater than chance probability (>17%) for the total sample and selected for FACT Prostate Symptom Index (FAPSI)-8 (Please see Additional File 1 [Appendix])
Summary
The objective of this study was to construct and validate a brief, clinically-relevant symptom index for advanced prostate cancer. The literature contains a number of reliable and valid instruments to measure quality of life (QOL) [5,6,7,8], oncology health care experts and regulatory agencies have resisted using these multi-item, multi-dimensional instruments in clinical practices and decision-making [9,10,11,12] This resistance stems from time and resource constraints [13,14], difficulty interpreting the meaning of multidimensional information, and difficulty determining the clinical meaning of score changes, including implications for treatment decisions [12,15,16,17,18,19,20]. The FDA Oncology Drug Advisory Committee subcommittee on Quality of Life has suggested that assessment of symptoms might represent a reasonable place to start in working toward a goal of more focused assessment of QOL domains [23]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
